Published On: 8/21/2024
Target RWE Announces the Launch of engage™ - An Innovative, Digital Patient-Centric Engagement Platform
Simplified, scalable, and flexible interventional tool to collect patient-reported outcome measures and clinician-reported outcomes beyond the standard of care
DURHAM, N.C., Aug. 21, 2024 /PRNewswire/ -- Real-world evidence (RWE) leader, Target RWE, today announced its new patient-centric platform engage™ - utilized by both patients and study sites to seamlessly capture digital, protocol-specific patient-reported outcome (PRO) measures and clinician-reported outcomes (ClinROs) in the real world.
"We are excited to launch engage™ which will be instrumental in supporting our ongoing strategic partnership with the American Association of the Study of Liver Disease (AASLD) and their Cirrhosis Quality Collaborative (CQC) initiatives," said Target RWE Chief Medical Officer Michael W. Fried, MD, FAASLD. "Initial deployments of our new platform have already demonstrated improved patient adherence and increased completion rates of patient-reported outcomes among patients with cirrhosis in our TARGET-LIVER DISEASE registry."
Developed to empower patients to actively participate in Target RWE registries, engage™ is supported by highly engaged study sites across the U.S. to streamline PRO measure data collection beyond the standard of care. The proprietary platform allows study sites to digitally capture patient consent forms, integrate ClinROs into workflows, and provide patient compensation via Paypal and/or Venmo for eligible completed milestones.
"Today's announcement represents a significant milestone in Target RWE's mission to advance the generation of real-world evidence and enhance the collection of meaningful patient data beyond electronic medical records," said Target RWE Chief Executive Officer Derek Evans. "By placing patients at the center of our real-world registries, we are fostering improved patient engagement and acceleration of insights to transform clinical practice and improve patient outcomes."
Key features include:
- User-friendly platform: Patients can easily access and securely contribute health information through an accessible mobile app or web portal.
- Rapid patient enrollment & easy management: Patients can self-enroll and submit required consent forms – with a dashboard view of all enrolled patients and milestones accessible for study sites.
- Flexible data collection: engage™ provides an intuitive, easy-to-use solution for study sites to customize study design and data collection schedules.
- Streamlined operations: Sites can reduce administrative burden and save time with digital survey completion, automated payments, and more efficient management of PROs, ClinROs, and biospecimens.
The collaborative engage™ platform helps ensure real-world data collected from Target RWE patient registries is of the highest quality and relevance, ultimately leading to more meaningful and impactful RWE.
To learn more about the solution and how it can transform RWE, please visit https://targetrwe.com/ or contact our team at info@targetrwe.com.
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
10/09/2024
Advancing RWE: Target RWE's Staging and Clean Room Committee Approaches Set New Benchmark -
08/27/2024
ISPE 2024 Research: Presentation by Kathleen Hurwitz ScD, Catherine Wiener, and Chase Latour -
08/21/2024
Target RWE Announces the Launch of engage™ - An Innovative, Digital Patient-Centric Engagement Platform -
08/21/2024
Sequential Nested Trial Emulation Presented by Real-World Evidence Leader Target RWE at ISPE 2024 -
06/12/2024
Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic Definitions